

CEO and Managing Director AGM Speech

Hi Everybody,

I'm delighted to be here today at the 2019 AGM to provide a short message prior to Dr Sud Agarwal presenting on the medicinal cannabis business in more depth. It's obviously been a highly eventful year for Impression Healthcare with a truly ambitious and value-driven company emerging.

Firstly, I want to reiterate that our oral devices business has experienced further sales growth, as outlined in the annual report. And a lot of care and attention has been placed in ensuring that the business is running efficiently and operating under best practices.

We've undertaken an aggressive international expansion plan that has included the initiation of our new Chinese manufacture base and the commencement of sales into Asia and even the USA. Our B2B network of dentists under the preferred practitioner network is always expanding.

The Fitguard by Gameday "smart" mouthguard that monitors concussion is the "best in class" and a major opportunity for Impression as parents and players focus more attention on safety.

Moving on to our wholly owned medicinal cannabis business, Incannex, I'd like to say that we've expanded the medical and scientific expertise of the Company enormously. The individuals on our advisory board are some of the best operators in their respective fields and internationally respected.

That injection of expertise and credibility has allowed us to seize the opportunity to expand the clinical program in a major way, allowing us the chance to eventually seek registration for our unique cannabinoid products under development.

We've commenced a patent program so that we can protect the investment in our work. API products are purchased or in train as initial formulations are set or being set to commence the journey of both pre-clinical studies and in-human observations.

A very important point that I wish to emphasise is that IHL through Incannex retains the capacity to sell our medicinal cannabis products under the Special Access Scheme, despite adjustments to the clinical program. Those adjustments mean that we can now pursue truly global opportunities.

Lastly, I'd also like to say that we do expect our first batch of medicinal cannabis oils in the week of the 14th of October. Sales of CBD oils and other cannabinoid products have been growing rapidly and there has been pressure on some existing suppliers to meet demand, which I believe will accentuate that opportunity for IHL.

Thank you,

Mr Joel Latham, CEO and Managing Director.